RISK OF RECURRENCE AMONG PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Ramirez, Oliva A. [1 ]
Law, E. H. [2 ]
Cueto, J. [2 ]
Salvo, E. M. [1 ]
Situ, A. [1 ]
Samjoo, I. A. [1 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN43
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [11] The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
    Xiewei Huang
    Yushuai Yu
    Shiping Luo
    Wenfen Fu
    Jie Zhang
    Chuangui Song
    BMC Cancer, 24
  • [12] How we treat HR-positive, HER2-negative early breast cancer
    Lopez-Tarruella, Sara
    Echavarria, Isabel
    Jerez, Yolanda
    Herrero, Blanca
    Gamez, Salvador
    Martin, Miguel
    FUTURE ONCOLOGY, 2022, 18 (08) : 1003 - 1022
  • [13] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [14] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [15] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [16] RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients
    Wang, Haibo
    Ma, Li
    Zhang, Yanan
    Wang, Ouchen
    Wei, Zhimin
    Xie, Xiaohong
    Zha, Xiaoming
    Zeng, Jian
    Lv, Qing
    Ren, Yu
    Wang, Huimin
    Du, Furong
    Cao, Shangzhi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [17] Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
    Shen, Xia-Bo
    Li, Guang-Liang
    Zheng, Ya-Bing
    Chen, Zhan-Hong
    Cao, Wen-Ming
    Wang, Xiao-Jia
    Shao, Xi-Ying
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [18] EU-Approval for Ibrance for Therapy of Patients with HR-positive/HER2-negative Breast Cancer
    Janik, Achim
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 67 - 67
  • [19] Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
    Xiewei Huang
    Yushuai Yu
    Shiping Luo
    Wenfen Fu
    Jie Zhang
    Chuangui Song
    BMC Cancer, 24 (1)
  • [20] Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.
    Shen, Xia-Bo
    Li, Guang-Liang
    Zheng, Ya-Bing
    Chen, Zhan-Hong
    Cao, Wen-Ming
    Shao, Xi-Ying
    Wang, Xiao-Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345